Register Interest

Kinoxis Therapeutics Pty Ltd

Kinoxis Therapeutics is a pre-clinical stage, private biotechnology company based in Australia that is developing of a range of novel therapeutic compounds for the treatment of substance use disorders and other CNS conditions. The company’s lead candidate, KNX100, is being developed for the treatment of opioid withdrawal and is undergoing pre-clinical testing, with the accompany on track to commence a Phase 1 human trial in late 2020.